Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 7 (2010), Issue 1 (January)

1. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment.
   Jpn J Clin Oncol, 40(1): 36-41. [Abstract] [Full-text]
2. Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response.
   Int J Cancer, 126(5): 1246-55. [Abstract] [Full-text]
3. Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer.
   Cancer Res, 70(1): 221-8. [Abstract] [Full-text]
4. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
   J Natl Cancer Inst, 102(1): 26-38. [Abstract] [Full-text]
5. Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.
   Br J Cancer, 102(1): 87-96. [Abstract] [Full-text]
6. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.
   J Clin Oncol, 28(2): 222-31. [Abstract] [Full-text]
7. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
   J Clin Oncol, 28(2): 240-4. [Abstract] [Full-text]
8. Uterine tumors resembling ovarian sex cord tumors: an ultrastructural analysis of 13 cases.
   Ultrastruct Pathol, 34(1): 16-24. [Abstract] [Full-text]
9. A case of luteinizing thecoma with sclerosing peritonitis: revisiting a link with anti-epileptic drugs.
   Pediatr Blood Cancer, 54(3): 470-2. [Abstract] [Full-text]
10. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis.
    Cell, 140(1): 49-61. [Abstract] [Full-text]
11. Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer.
    Cancer Genet Cytogenet, 196(2): 146-52. [Abstract] [Full-text]
12. Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells.
    Mol Pharmacol, 77(2): 298-310. [Abstract] [Full-text]
13. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Cancer Chemother Pharmacol, 65(4): 679-86. [Abstract] [Full-text]
14. Protease inhibitor SERPINA1 expression in epithelial ovarian cancer.
    Clin Exp Metastasis, 27(1): 55-69. [Abstract] [Full-text]
15. Precursors of endometrial and ovarian carcinoma.
    Virchows Arch, 456(1): 1-12. [Abstract] [Full-text]
16. Cytotoxicity, hydrophobicity, uptake, and distribution of osmium(II) anticancer complexes in ovarian cancer cells.
    J Med Chem, 53(2): 840-9. [Abstract] [Full-text]
17. MRI of endometriotic cysts in association with ovarian carcinoma.
    AJR Am J Roentgenol, 194(2): 355-61. [Abstract] [Full-text]
18. New frontiers for ovarian cancer risk evaluation: proteomics and contrast-enhanced ultrasound.
    AJR Am J Roentgenol, 194(2): 349-54. [Abstract] [Full-text]
19. Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with microbubbles.
    AJR Am J Roentgenol, 194(2): 343-8. [Abstract] [Full-text]
20. Clinical decision making using ovarian cancer risk assessment.
    AJR Am J Roentgenol, 194(2): 337-42. [Abstract] [Full-text]
21. Current update on borderline ovarian neoplasms.
    AJR Am J Roentgenol, 194(2): 330-6. [Abstract] [Full-text]
22. Ultrasound and assessment of ovarian cancer risk.
    AJR Am J Roentgenol, 194(2): 322-9. [Abstract] [Full-text]
23. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization.
    AJR Am J Roentgenol, 194(2): 311-21. [Abstract] [Full-text]
24. Risk assessment and genetic testing for ovarian cancer.
    AJR Am J Roentgenol, 194(2): 309-10. [Abstract] [Full-text]
25. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.
    J Cancer Res Clin Oncol, 136(3): 447-56. [Abstract] [Full-text]
26. Investigation of patients with atypical or severe hyperandrogenaemia including androgen-secreting ovarian teratoma.
    Eur J Endocrinol, 162(2): 213-20. [Abstract] [Full-text]
27. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.
    J Surg Oncol, 101(2): 149-55. [Abstract] [Full-text]
28. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
    Int J Cancer, 126(6): 1378-89. [Abstract] [Full-text]
29. Role of the otolaryngologist in the treatment of struma ovarii.
    Laryngoscope, 120(2): 259-60. [Abstract] [Full-text]
30. Changes in expression, and/or mutations in TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human ovarian tumors.
    J Cancer Res Clin Oncol, 136(3): 351-61. [Abstract] [Full-text]
31. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
    Gynecol Oncol, 116(2): 157-62. [Abstract] [Full-text]
32. Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer.
    Gynecol Oncol, 116(2): 276-81. [Abstract] [Full-text]
33. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
    Gynecol Oncol, 116(2): 213-21. [Abstract] [Full-text]
34. Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
    Gynecol Oncol, 116(2): 269-75. [Abstract] [Full-text]
35. The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer.
    Gynecol Oncol, 116(2): 282-5. [Abstract] [Full-text]
36. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.
    Gynecol Oncol, 116(2): 168-72. [Abstract] [Full-text]
37. BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells.
    Gynecol Oncol, 116(2): 262-8. [Abstract] [Full-text]
38. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
    Gynecol Oncol, 116(2): 202-7. [Abstract] [Full-text]
39. Current state of biomarker development for clinical application in epithelial ovarian cancer.
    Gynecol Oncol, 116(2): 240-5. [Abstract] [Full-text]
40. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.
    Gynecol Oncol, 116(2): 195-201. [Abstract] [Full-text]
41. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
    Hum Pathol, 41(2): 255-61. [Abstract] [Full-text]
42. Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
    J Clin Oncol, 28(4): 675-82. [Abstract] [Full-text]
43. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.
    Clin Chem, 56(2): 262-71. [Abstract] [Full-text]
44. Biological effects of combined ultrasound and cisplatin treatment on ovarian carcinoma cells.
    Ultrasonics, 50(3): 357-62. [Abstract] [Full-text]

© 2004-2012 Ovarian Cancer Research Today. All Rights Reserved.